logo-loader

Futura Medical advancing commercial discussions and planning further launches

Published: 22:49 14 Mar 2018 AEDT

Picture of Futura Medical

Futura Medical PLC’s (LON:FUM) CEO James Barder tells Proactive’s Andrew Scott negotiations over a deal with a partner that would help commercialise their breakthrough erectile dysfunction treatment are at an advanced stage.

MED2002 is a rapid onset gel designed for those men where the current pill-based treatments aren’t appropriate or carry significant side-effects.

The update came a day after Futura announced interim data which indicated its lead drug can be administered in at least two higher-strength doses.

This has a knock-on positive impact for the imminent phase III clinical trial of MED2002, which is hoped will rubber stamp its huge potential.

Futura Medical kicks off work on Phase III trial for erectile dysfunction gel

James Barder, chief executive of Futura Medical PLC (LON:FUM), tells Proactive they've begun preparatory work on the first Phase III efficacy trial for MED2002 - their topical gel for erectile dysfunction (ED). The study will recruit approximately 1,000 patients with mild, moderate and...

on 27/4/18